Desiccated Thyroid

Desiccated thyroid, also known as natural desiccated thyroid (NDT), is a hormone replacement therapy derived from the dried thyroid glands of pigs, containing a mixture of levothyroxine (T4) and liothyronine (T3). Researchers primarily study desiccated thyroid for its efficacy in managing hypothyroidism, particularly in patients who do not respond adequately to synthetic levothyroxine alone. Key findings from comparative studies indicate that while overall outcomes among patients using desiccated thyroid, levothyroxine, and a combination of both are similar, those who are more symptomatic on levothyroxine may prefer and respond positively to desiccated thyroid or a combination therapy including T3. Current research continues to explore the potential benefits of desiccated thyroid, particularly in specific patient populations, highlighting its clinical relevance in the context of individualized treatment approaches for hypothyroidism.

Desiccated thyroid, also known as natural desiccated thyroid (NDT) or Armour Thyroid, is a synthetic hormone replacement derived from the dried thyroid glands of pigs. It belongs to the chemical class of thyroid hormones, specifically containing both thyroxine (T4) and triiodothyronine (T3). This compound is used to supplement or replace endogenous thyroid hormones in individuals with hypothyroidism, a condition characterized by insufficient thyroid hormone production. Researchers have focused on its role in managing symptoms of hypothyroidism, particularly in patients who do not respond well to levothyroxine alone. The primary physiological role of desiccated thyroid is to mimic the natural secretion of thyroid hormones, thereby regulating metabolism, energy production, and overall endocrine function. Research has explored its effectiveness compared to other thyroid hormone therapies, such as levothyroxine and combinations of levothyroxine with liothyronine. Desiccated thyroid acts primarily on thyroid hormone receptors, which are nuclear receptors that regulate gene expression. Upon binding to these receptors, T3 and T4 influence the transcription of genes involved in metabolic processes. This leads to increased basal metabolic rate, protein synthesis, and sensitivity to catecholamines. The pharmacokinetic properties of desiccated thyroid include its oral bioavailability, which is generally good, although individual absorption can vary. The half-life of T4 in desiccated thyroid is approximately 7 days, while T3 has a shorter half-life of about 1 day. Metabolism occurs primarily in the liver, where T4 is converted to T3. Clinically, desiccated thyroid is used for the treatment of hypothyroidism, particularly in patients who do not achieve symptom relief with levothyroxine alone. It is regulated as a prescription medication in many countries, with varying legal statuses depending on regional regulatory bodies. Researchers have observed that while some patients report symptom improvement with desiccated thyroid, its use should be carefully considered alongside other treatment options.

Desiccated thyroid acts on thyroid hormone receptors, which are nuclear receptors that modulate gene expression. The binding of T3 and T4 to these receptors initiates a biological cascade that enhances metabolic rate, protein synthesis, and sensitivity to catecholamines, thereby influencing energy metabolism and growth.

Desiccated thyroid extract (DTE) primarily exerts its effects through the activation of thyroid hormone receptors (TRs), specifically TRα and TRβ, which modulate gene expression involved in metabolic processes, growth, and development. This activation influences key signaling pathways, including the cAMP/PKA pathway and the regulation of the HPT axis, ultimately affecting basal metabolic rate, protein synthesis, and energy expenditure. While the precise mechanisms underlying the differential responses to DTE compared to synthetic levothyroxine are not fully understood, the presence of both thyroxine (T4) and triiodothyronine (T3) in DTE may contribute to its therapeutic effects in certain hypothyroid patients.

Current evidence is limited regarding the long-term efficacy and safety of desiccated thyroid extract (DTE) compared to levothyroxine and levothyroxine plus liothyronine in diverse populations, particularly in those with varying degrees of symptom severity. Further research is needed to conduct larger randomized controlled trials (RCTs) that specifically address the biochemical and metabolic impacts of DTE over extended periods, as well as to explore the genetic factors influencing individual responses to DTE therapy. Additionally, studies should investigate the long-term outcomes and quality of life in patients who prefer DTE, particularly among those who are symptomatic despite standard treatments.